Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 589,257 Shares

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the sale, the director directly owned 4,555,741 shares in the company, valued at $75,579,743.19. This trade represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Price Performance

NASDAQ:VOR opened at $16.27 on Tuesday. The firm’s 50 day simple moving average is $14.25 and its 200 day simple moving average is $17.35. Vor Biopharma Inc. has a one year low of $2.62 and a one year high of $65.80. The company has a market cap of $794.79 million, a PE ratio of -0.04 and a beta of 1.92.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Citigroup assumed coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wedbush lifted their target price on shares of Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VOR. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma in the 4th quarter worth approximately $36,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the 2nd quarter worth approximately $66,000. Chung Wu Investment Group LLC acquired a new position in shares of Vor Biopharma in the 4th quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Vor Biopharma in the 4th quarter worth approximately $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).